McKesson Corporation

NYSE:MCK Rapporto sulle azioni

Cap. di mercato: US$71.0b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

McKesson Gestione

Gestione criteri di controllo 2/4

McKesson's Il CEO è Brian Tyler, nominato in Apr2019, e ha un mandato di 5.33 anni. la retribuzione annua totale è $ 19.00M, composta da 7.8% di stipendio e 92.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.064% delle azioni della società, per un valore di $ 45.21M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.3 anni e 2.9 anni.

Informazioni chiave

Brian Tyler

Amministratore delegato

US$19.0m

Compenso totale

Percentuale dello stipendio del CEO7.8%
Mandato del CEO5.3yrs
Proprietà del CEO0.06%
Durata media del management3.3yrs
Durata media del Consiglio di amministrazione2.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

McKesson Corporation (NYSE:MCK) Not Lagging Market On Growth Or Pricing

Aug 22
McKesson Corporation (NYSE:MCK) Not Lagging Market On Growth Or Pricing

McKesson Corporation: An Interesting Health Giant With A Hidden Gem

Jul 04

With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For

May 09
With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For

Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?

Mar 14
Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?

McKesson: GLP-1 Contributed More Than 1/3 Of Growth

Feb 19

McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues

Feb 16
McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues

Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking

Jan 29
Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking

McKesson: Why The Company Is Too Richly Valued

Jan 19

If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity

Nov 20
If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity

McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase

Nov 08

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?

Oct 30
Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?

McKesson: Still Trading For A Huge Discount

Sep 06

Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

Aug 21
Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?

Jul 27
Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?

McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation

Jun 28

Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

May 23
Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?

Apr 17
Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?

Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?

Feb 22
Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?

McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth

Feb 08

McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M

Feb 01

McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price

Jan 12
McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price

5 Reasons Why I Am Considering Adding McKesson To My Portfolio

Dec 27

McKesson Corporation: Still Trading Below Intrinsic Value

Dec 13

Duration: The Time Bomb In Your Portfolio - McKesson And PayPal In Focus

Oct 08

McKesson extends distribution partnership with CVS Health

Sep 29

An Intrinsic Calculation For McKesson Corporation (NYSE:MCK) Suggests It's 50% Undervalued

Sep 19
An Intrinsic Calculation For McKesson Corporation (NYSE:MCK) Suggests It's 50% Undervalued

McKesson to acquire Rx Savings Solutions in $875M deal

Sep 19

Cardinal Health, McKesson hit 52-week highs; up 35% and 50% YTD

Aug 15

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Brian Tyler rispetto agli utili di McKesson?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

US$3b

Mar 31 2024US$19mUS$1m

US$3b

Dec 31 2023n/an/a

US$3b

Sep 30 2023n/an/a

US$3b

Jun 30 2023n/an/a

US$4b

Mar 31 2023US$20mUS$1m

US$4b

Dec 31 2022n/an/a

US$3b

Sep 30 2022n/an/a

US$2b

Jun 30 2022n/an/a

US$1b

Mar 31 2022US$18mUS$1m

US$1b

Dec 31 2021n/an/a

US$1b

Sep 30 2021n/an/a

-US$5b

Jun 30 2021n/an/a

-US$4b

Mar 31 2021US$15mUS$1m

-US$5b

Dec 31 2020n/an/a

-US$4b

Sep 30 2020n/an/a

US$2b

Jun 30 2020n/an/a

US$922m

Mar 31 2020US$15mUS$1m

US$906m

Dec 31 2019n/an/a

-US$905m

Sep 30 2019n/an/a

-US$626m

Jun 30 2019n/an/a

US$601m

Mar 31 2019US$13mUS$929k

US$33m

Compensazione vs Mercato: La retribuzione totale di Brian ($USD 19.00M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 13.21M ).

Compensazione vs guadagni: La retribuzione di Brian è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Brian Tyler (57 yo)

5.3yrs

Mandato

US$18,997,543

Compensazione

Mr. Brian S. Tyler, Ph D., has been an Independent Director at Republic Services, Inc. since April 1, 2021. He served as Chairman of Supervisory Board at McKesson Europe AG since August 9, 2018 until 2022....


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Brian Tyler
CEO & Director5.3yrsUS$19.00m0.064%
$ 45.2m
Britt Vitalone
Executive VP & CFO6.6yrsUS$6.78m0.011%
$ 8.0m
Michele Lau
Executive VP & Chief Legal Officerless than a yearUS$8.81m0.00011%
$ 78.1k
LeAnn Smith
Executive VP & Chief Human Resources Officer1.7yrsUS$3.54m0.0016%
$ 1.1m
Thomas Rodgers
Executive VP and Chief Strategy & Business Development Officer4.2yrsUS$3.18m0.0020%
$ 1.4m
Napoleon Rutledge
Senior VP2.4yrsNessun dato0.0015%
$ 1.1m
Francisco Fraga
Executive VPless than a yearNessun datoNessun dato
Rachel Rodriguez
Vice President of Investor Relationsno dataNessun datoNessun dato
Pete Slone
Senior Vice President of Corporate Public Affairs9.2yrsNessun datoNessun dato
Kirk Kaminsky
President of The US Pharmaceutical & Specialty Solutions Business5.3yrsNessun datoNessun dato
Paul Smith
Senior Vice President of Taxesno dataNessun datoNessun dato
Kevin Emerson
Senior Vice President of Finance Operations2.4yrsNessun datoNessun dato

3.3yrs

Durata media

51.5yo

Età media

Gestione esperta: Il team dirigenziale di MCK è considerato esperto (durata media dell'incarico 3.3 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Brian Tyler
CEO & Director5.3yrsUS$19.00m0.064%
$ 45.2m
Donald Knauss
Independent Chairman of the Board9.8yrsUS$555.22k0.0016%
$ 1.1m
Maria Martinez
Independent Director4.8yrsUS$335.08k0.00027%
$ 191.7k
Dominic Caruso
Independent Director5.9yrsUS$336.21k0.00027%
$ 191.7k
Deborah Dunsire
Directorless than a yearNessun datoNessun dato
James Hinton
Independent Director2.6yrsUS$315.08k0%
$ 0
Webster Dunbar
Independent Director2.3yrsUS$315.08k0%
$ 0
Kathleen Wilson-Thompson
Independent Director2.6yrsUS$315.08k0%
$ 0
Richard Carmona
Independent Director2.9yrsUS$313.71k0%
$ 0
Kevin Ozan
Independent Directorless than a yearUS$139.34k0.000010%
$ 7.1k
Bradley Lerman
Independent Director6.3yrsUS$328.71k0%
$ 0

2.9yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di MCK non è considerato esperto (durata media del mandato 2.9 anni), il che suggerisce un nuovo consiglio.